Meridian Bioscience (VIVO) vs. Landauer (LDR) Head to Head Analysis

Meridian Bioscience (NASDAQ: VIVO) and Landauer (NYSE:LDR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Valuation & Earnings

This table compares Meridian Bioscience and Landauer’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Meridian Bioscience $200.77 million 3.10 $21.55 million $0.51 28.82
Landauer N/A N/A N/A $1.92 35.00

Meridian Bioscience has higher revenue and earnings than Landauer. Meridian Bioscience is trading at a lower price-to-earnings ratio than Landauer, indicating that it is currently the more affordable of the two stocks.


This table compares Meridian Bioscience and Landauer’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Meridian Bioscience 10.74% 17.03% 11.51%
Landauer 16.55% 96.20% 13.62%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Meridian Bioscience and Landauer, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Meridian Bioscience 1 3 0 0 1.75
Landauer 0 1 0 0 2.00

Meridian Bioscience currently has a consensus target price of $11.50, suggesting a potential downside of 21.77%. Given Meridian Bioscience’s higher possible upside, equities research analysts plainly believe Meridian Bioscience is more favorable than Landauer.

Institutional and Insider Ownership

86.8% of Meridian Bioscience shares are owned by institutional investors. Comparatively, 79.6% of Landauer shares are owned by institutional investors. 2.7% of Meridian Bioscience shares are owned by company insiders. Comparatively, 6.6% of Landauer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


Meridian Bioscience pays an annual dividend of $0.50 per share and has a dividend yield of 3.4%. Landauer pays an annual dividend of $1.10 per share and has a dividend yield of 1.6%. Meridian Bioscience pays out 98.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Landauer pays out 57.3% of its earnings in the form of a dividend.

Risk and Volatility

Meridian Bioscience has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Landauer has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500.


Landauer beats Meridian Bioscience on 9 of the 13 factors compared between the two stocks.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.

Landauer Company Profile

Landauer, Inc. is a provider of technical and analytical services to determine occupational and environmental radiation exposure. The Company is a provider of outsourced medical physics services, and a provider of radiology related medical products. The Company operates through three segments: Radiation Measurement, Medical Physics and Medical Products. The Company provides radiation dosimetry services to hospitals, medical and dental offices, universities, national laboratories, nuclear facilities and other industries. Medical physics services are provided through the Company’s Landauer Medical Physics (LMP) division. The Company uses LMP as a platform to expand into the medical physics services market, serving domestic hospitals, radiation therapy centers and imaging centers. The Company’s Medical Products segment provides medical consumable accessories used in radiology, radiation therapy and image guided surgery procedures.

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with's FREE daily email newsletter.

Leave a Reply